People In The News

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and that he will become a director at the firm upon approval. Markison currently is chairman and CEO of King Pharmaceuticals, where he led the company through to its recently announced acquisition by Pfizer, and before that he was at Bristol-Myers Squibb, where he served as president of BMS Oncology/Virology and Oncology Therapeutics Network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.